NCT05971589尚未招募早期 1 期
An Exploratory Clinical Study Evaluating the Safety, Tolerance, Immune Response, and Initial Efficacy of Autologous Tumor Infiltrating Lymphocytes (TILs) LM103 Injection in Patients With Advanced Solid Tumors
Suzhou BlueHorse Therapeutics Co., Ltd.0 个研究点目标入组 5 人开始时间: 2023年8月1日最近更新:
适应症
试验速览
- 阶段
- 早期 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 5
- 主要终点
- Adverse events (AE), Serious adverse event (SAE) and immune related adverse events (irAE)
研究概览
简要总结
This study is an open exploratory clinical study to evaluate the safety, tolerance, immune response, and initial efficacy of autologous tumor infiltrating lymphocyte LM103 injection in advanced solid tumor patients. The research treatment includes fludarabine and cyclophosphamide, autologous tumor infiltrating lymphocytes (TILs) infusion, and Interleukin-2 therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The expected survival time is not less than 6 months.
- •Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0-
- •Patients with advanced solid tumors confirmed by histology or cytology: advanced Melanoma, head and neck squamous cell cancer, soft tissue sarcoma and other solid tumors that have failed standard treatment regimens, cannot tolerate standard treatment, refuse or do not have standard treatment regimens available.
- •The patient has lesions that can be used for surgical resection (>1.5 cm^3) or biopsy puncture (no less than 6 lesions) for TILs collection.
- •At least one measurable lesion as the target lesion after collecting tumor tissue from the patient (RECIST v1.1 criteria).
- •Laboratory tests results during the screening period indicate that the subjects have sufficient organ function.
排除标准
- •Have a medical history of other malignant tumors other than the disease under study in the past 5 years, except for malignant tumors that can be expected to recover after treatment (including but not limited to thyroid cancer, cervical Carcinoma in situ, basal or squamous cell skin cancer or Ductal carcinoma in situ of the breast treated by radical surgery).
- •LM103 received systematic Sex therapy of antineoplastic drugs (including chemotherapy, small molecule targeted drug therapy, Hormone replacement therapy, etc.), or local antineoplastic therapy (such as radiotherapy, palliative radiotherapy for bone metastases>2 weeks before the start of the study and intracranial stereotactic radiotherapy or resection of a single brain metastasis>3 weeks before the start of the study were acceptable) within 4 weeks before LM103 infusion; Or received clinical investigational drugs or equipment treatment.
- •Adverse reactions caused by previous treatment have not recovered to CTCAE (version 5.0) level 1 or below (excluding hair loss and neurotoxicity, which have been determined by the researchers to be irreparable and level 2 hypothyroidism for a long time).
- •Previously received allogeneic hematopoietic stem cell transplantation or solid organ transplantation.
结局指标
主要结局
Adverse events (AE), Serious adverse event (SAE) and immune related adverse events (irAE)
时间窗: through study completion, an average of 1 year estimate
Incidence and severity of AE, SAE and irAE; Abnormal changes in laboratory and other tests with clinical significance.
次要结局
- Time to response (TTR)(through study completion, an average of 1 year estimate)
- Time to disease progression (TTP)(through study completion, an average of 1 year estimate)
- Peripheral blood TILs cell survival(through study completion, an average of 1 year estimate)
- Duration of response (DOR)(through study completion, an average of 1 year estimate)
- Overall survival (OS)(through study completion, an average of 1 year estimate)
- Objective response rate (ORR)(through study completion, an average of 1 year estimate)
- Disease control rate (DCR)(through study completion, an average of 1 year estimate)
- Progression free survival (PFS)(through study completion, an average of 1 year estimate)
研究者
相似试验
招募中
早期 1 期
A Clinical Study on LM103 for the Treatment of Advanced Solid TumorsSolid TumorNCT05941936Suzhou BlueHorse Therapeutics Co., Ltd.5
尚未招募
早期 1 期
A Clinical Study on TILs for the Treatment of Advanced Solid TumorsSolid TumorNCT05971576Suzhou BlueHorse Therapeutics Co., Ltd.20
招募中
1 期
An Exploratory Clinical Study to Evaluate the Safety, Tolerability, Immune Response and Preliminary Efficacy of LM103 Injection in Combination With PD-1 in Patients With Advanced Solid TumoursSolid CancerNCT06697665Suzhou BlueHorse Therapeutics Co., Ltd.10
Unknown
1 期
UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid TumorsMesothelin-positive Advanced Malignant Solid TumorsNCT05848999Zhejiang University87
尚未招募
1 期
UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid TumorsSolid TumorNCT05775666Peking University87